Introduction {#Sec1}
============

PARK9, or Kufor-Rakeb syndrome (KRS), is characterized by juvenile-onset, levodopa-responsive parkinsonism, pyramidal signs, dementia, and supranuclear gaze palsy \[[@CR1], [@CR2]\], caused by recessive mutations in the *ATP13A2* gene \[[@CR3]\]. Since the initial report, only six definitely disease-causing (homozygous or compound heterozygous) mutations have been described in two families \[[@CR3]\] and three isolated KRS patients \[[@CR4]--[@CR6]\]. For another seven mutations identified in single heterozygous state in patients with early-onset Parkinson's disease (PD) \[[@CR4], [@CR7], [@CR8]\], the role in the disease causation remains unclear.

The *ATPA13A2* gene encodes a large lysosomal transmembrane protein, belonging to the group 5 P-type ATPase family. P-type ATPases use the energy deriving from ATP hydrolysis to generate gradients of ions across membranes \[[@CR9]\]. The substrate specificity of the ATP13A2 protein remains unknown, but there is evidence that this protein is involved in the transport of several cations from the cytosol to the lysosomal lumen, including manganese, cadmium, nickel, and selenium \[[@CR10], [@CR11]\].

Recessive mutations in the *FBXO7* gene have been recently linked to PARK15, a different rare juvenile neurodegenerative disorder, presenting as a parkinsonian-pyramidal syndrome and reported so far in only three families \[[@CR12], [@CR13]\].

In this study, we describe two brothers from a southern Italian family, who both carry a novel homozygous *ATP13A2* mutation and a single heterozygous *FBXO7* mutation. Despite the identical genotypes, the brothers were affected with markedly different severity.

Subjects and methods {#Sec2}
====================

A simplified pedigree is shown in Fig. [1](#Fig1){ref-type="fig"}. A healthy couple had two offspring, who both developed different degrees of a progressive neurological disease. The parents report no known consanguinity, but they both originate from the same small village in the Campania region of southern Italy. The project was approved by the relevant ethical authorities, and written informed consent was obtained from all subjects. Fig. 1Genetic findings in the family with *PARK9* and *PARK15* mutations. **a** Electropherograms of a fragment of *ATP13A2* (*PARK9*) exon 24; *hom* homozygous mutation, *het* heterozygous mutation, *wt* wild-type sequence. **b** Simplified pedigree. The proband is highlighted by a *black symbol*; his brother is highlighted in *gray*. The *ATP13A2* (*PARK9*) and *FBXO7* (*PARK15*) mutations are shown below the individual symbols. **c** Electropherograms of a fragment of *FBXO7* (*PARK15*) exon 9; *het* heterozygous mutation, *wt* wild-type sequence. **d** Schematic representation of the ATP13A2 protein, its known functional domains and amino acid motifs. The position of the G877R mutation detected in the Italian family is indicated within the P2 domain and within the MCGDG motif (the mutated G is *underlined*). The other two missense mutations reported previously in homozygous state in PARK9 patients are also shown. **e** Schematic representation of the FBXO7 protein. The R481C mutation detected in the Italian family is framed. The other disease-causing mutations reported previously in PARK15 patients are also shown. **f** Alignment of ATP13A2 protein homologues in the region of the G877R mutation. **g** Alignment of P5-ATPase protein family in the region corresponding to the G877R mutation. **h** Alignment of FBXO7 protein homologues in the region of the R481C mutation

Genetic studies {#Sec3}
---------------

Genomic DNA was isolated from peripheral blood samples following standard procedures. We first screened the proband for mutations in the *parkin* (*PARK2*), *PINK1* (*PARK6*), *DJ*-*1* (*PARK7*), *ATP13A2* (*PARK9*), *PLA2G6* (*PARK14*), and *FBXO7* (*PARK15*) genes. All exons and exon--intron boundaries of the above-mentioned genes were sequenced in both strands. The PCR protocols and primers are available on request from the authors. Direct sequencing was performed using Big Dye Terminator chemistry ver.3.1 (Applied Biosystems). Fragments were loaded on an Applied Biosystems 3130XL automated sequencer and analyzed with DNA Sequencing Analysis (ver.5.3) and SeqScape (ver.2.6) software (Applied Biosystems). The mutations were numbered from the "A" of the ATG-translation initiation codon, according to the GenBank reference sequences, accession numbers NM_022089.2 (*ATP13A2*) and NM_012179.3 (*FBXO7*). We also screened the proband for copy number aberrations in the *parkin*, *PINK1*, *DJ*-*1*, *ATP13A2*, and *SNCA* (*alpha*-*synuclein*) genes, using a multiplex ligation-dependent probe amplification (MLPA) assay (probe mix P051 and P052) according to the manufacturer's protocol (MRC-Holland). The *PARK9* and *PARK15* mutations detected in the proband were studied in the whole family, as well as in a panel of unrelated healthy controls from the same region of southern Italy, and using the same sequencing techniques. In order to analyze the evolutionary conservation of the mutated amino acids, the ATP13A2 and FBXO7 protein homologues were aligned using the program ClustalW.

Brain imaging {#Sec4}
-------------

Brain single photon emission computed tomography (SPECT) studies were performed 4 h after intravenous administration of 185 MBq of \[123I\]FP-CIT (DaTSCAN, GE-Healthcare) using a dual-headed camera (E.CAM, Siemens Medical Systems, Hoffman Estates, IL) equipped with low-energy high-resolution collimators (zoom, 1.23; pixel size, 3.90 × 3.90 mm). Outcome measures were the specific-to-nondisplaceable binding ratio, *V*″~3~ for the putamen and caudate.

The brain MRI studies included T2-weighted turbo spin-echo (TSE) (TR/TE 4,400/100 ms) and FLAIR (TR/TE/TI 8,000/100/2,200 ms) sequences, as well as T1-weighted conventional SE (TR/TE 580/15 ms), and DWI (EPI, TR/TE 3,500/90 ms) images (1.5 T, Achieva, Philips Medical Systems, Eindhoven, Netherlands). In addition, T2\*-weighted axial images (Gradient echo, TR/TE 600/15 ms, Flip Angle 20°) were acquired (3 T, Magnetom Trio, Siemens Medical Systems, Erlangen, Germany).

Results {#Sec5}
=======

Clinical findings {#Sec6}
-----------------

The proband (NAPO-6 in Fig. [1](#Fig1){ref-type="fig"}) is a 41-year-old man with referred perinatal asphyxia and slight delay in reaching the developmental milestones. At the age of 10 years, he developed a slowly progressive gait disturbance with slowing and stiffness of legs. An asymmetric onset of symptoms was not recorded. Treatment with levodopa yielded marked improvement in gait and in limb rigidity. Nonetheless, over time, his motor performance progressively deteriorated, and a mild cognitive impairment became apparent. At the age of 18 year, he received the diagnosis of "extra-pyramidal and pyramidal syndrome with cognitive impairment". Since then, the patient complained of dysarthria and dysphagia, and some years later, the arm and leg stiffness became so severe to determine the complete dependence on others for all daily living activities. Our neurological examination, 30 years after the disease onset, showed a moderate limitation of the up-gaze and right lateral gaze. The saccadic eye movements were slow both in upward and downward direction and bilaterally hypometric on lateral gaze. A severe hypomimia was present, and the speech was almost incomprehensible. There was also mild dysphagia, allowing a normal feeding. Sub-continuous mini-myoclonus was present in the lower facial muscles. The gait was only possible with bilateral support, and dystonic posturing was present. The muscle tone was markedly increased in all limbs with prevalence of rigidity in the arms and spasticity in the legs. The deep tendon reflexes were all brisk, and the Babinski sign and palmomental reflex were present bilaterally. Cerebellar signs and tremor were absent. The unified PD rating scale (UPDRS) motor score was 67, and it was not modified by the acute administration of levodopa. The administration of the mini-mental state examination (MMSE) was not possible. Blood chemistry, including manganese, selenium, cadmium, and nickel dosage, was normal. Needle EMG (biceps brachii, rectus femori, and tibialis anterior muscles), surface antidromic sensory (median, ulnar, sural, and peroneal nerves) and orthodromic motor nerve (median, ulnar, and tibial nerves) conduction studies (NCS), and somatosensory evoked potentials (SSEPs) following median and tibial nerve were all normal. Transcranial Magnetic Stimulation (TMS) showed a prolonged central motor conduction time (CMCT) for upper (10.3 ms; normal upper limit, 8 ms) and lower (30.5 ms; normal upper limit, 15 ms) limbs, while motor evoked potential (MEP) amplitude was normal in the upper and reduced in the lower limbs (0.7 mV; normal lower limit, 1.2 mV).

The proband's brother (NAPO-7 in Fig. [1](#Fig1){ref-type="fig"}), a 31-year-old man, had a normal birth and developmental motor milestones, but he did not perform normally at school and received a diagnosis of "mild mental retardation". At the time of neurological examination (age 31), he was otherwise asymptomatic. However, the neurological evaluation showed a slight limitation of upward and downward gaze, moderate increase of axial tone, and slight upper limb rigidity. The deep tendon reflexes were brisk, and the Babinski sign was bilaterally present. Finger tapping and stepping were moderately decreased in frequency and amplitude. Cerebellar signs and tremor were absent. The UPDRS motor score was 16. He had never used antiparkinsonian drugs. The MMSE score was 23. Blood chemistry, including manganese, selenium, cadmium, and nickel dosage, was normal. Needle EMG (biceps brachii, rectus femori, and tibialis anterior muscles), surface antidromic sensory (median, ulnar, sural, and peroneal nerves) and orthodromic motor (median, ulnar, and tibial nerves) NCS, and SSEPs following median and tibial nerve were normal. TMS showed a prolonged CMCT for upper (11.8 ms; normal upper limit, 8 ms) and lower (24.2 ms; normal upper limit, 15 ms) limbs, while MEP amplitude was normal in the upper and reduced in the lower limbs (0.4 mV; normal lower limit, 1.2 mV).

Genetic findings {#Sec7}
----------------

By sequencing the genomic DNA in the proband, we detected a homozygous mutation in exon 24 of the *ATP13A2* gene (c.G2629A, predicted to lead to the p.G877R missense change in the encoded protein) and a heterozygous mutation in exon 9 of the *FBXO7* gene (c.C1441T, predicted to result in the missense change p.R481C) (Fig. [1a--c](#Fig1){ref-type="fig"}). Direct sequencing revealed no additional mutations in these or other screened genes for autosomal recessive parkinsonism (*parkin*, *PINK1*, *DJ*-*1*, *PLA2G6*). Furthermore, gene dosage aberrations were not detected by the MLPA assays in any of the screened genes. The *ATP13A2* c.G2629A mutation was detected in heterozygous state in both the proband's parents, while it was absent from a large number of control chromosomes (*n* = 336) from the same region of southern Italy. The *FBXO7* c.C1441T mutation was detected in heterozygous state in the proband's mother, while it was absent from the father and from control chromosomes from the region (*n* = 318). The proband's brother (NAPO-7) carried a homozygous *ATP13A2* and heterozygous *FBXO7* mutation, a situation identical to that found in the proband (Fig. [1b](#Fig1){ref-type="fig"}). The cDNA studies confirmed the genotypes detected in genomic DNA in the whole family (not shown). Both mutations introduce drastic replacements in amino acid positions that have been highly conserved in the evolution of the ATP13A2 and FBXO7 protein homologues (Fig. [1d--h](#Fig1){ref-type="fig"}).

Imaging findings {#Sec8}
----------------

The \[123I\]FP-CIT--SPECT showed in both brothers a decrease of dopamine transporter (DaT) density in the striatum (Fig. [2](#Fig2){ref-type="fig"}). Compared to controls, the proband showed a marked and widespread striatal reduction of *V*″~3~ (75% in the caudate and 85% in the putamen) (Fig. [2a](#Fig2){ref-type="fig"}). In the brother, the specific-to-nondisplaceable binding ratio *V*″~3~ was also symmetrically reduced, mostly in the putamen (40% in the caudate and 65% in the putamen) (Fig. [2b](#Fig2){ref-type="fig"}). In both brothers the brain MRI showed diffuse cerebral and cerebellar cortex atrophy, which was more severe in the proband (Fig. [3](#Fig3){ref-type="fig"}). The T2\* scans detected no evidence of metal accumulation in the basal ganglia of both sibs (Fig. [3c, f](#Fig3){ref-type="fig"}). Fig. 2DaTSCAN SPECT imaging. Brain \[123I\]FP-CIT (DaTSCAN SPECT) in the proband (**a**), his brother (**b**), and a normal unrelated subject (**c**); a severe presynaptic defect of the nigrostriatal dopaminergic systems is present in the two brothers, more marked in the probandFig. 3Brain MRI imaging. T2-weighted TSE axial scans (1.5 T) at the level of the cerebellar hemispheres (**a, d**) and centra semiovalia (**b, e**) and T2\*-weighted scans (3 T) at the level of the basal ganglia (**c**, **f**), in the proband (**a**--**c**) and his brother (**d**--**f**). Diffuse supra- and sub-tentorial atrophy is present. The T2\*-weighted scans show normal intensity of the basal ganglia in both individuals. Incidental left maxillary sinusitis is also present (**d**)

Discussion {#Sec9}
==========

Several arguments support the view that the G877R mutation is harmful for the ATP13A2 protein function. The glycine 877 lies in a stretch of five amino acids that have not only been conserved in the evolution of ATP13A2 homologues until the yeasts but are also invariably present in all members of the ATPase P5 protein family (Fig. [1f--g](#Fig1){ref-type="fig"}), suggesting a crucial role for the protein function. Furthermore, the G877R mutation replaces a small non-polar amino acid (glycine) with a larger polar one (arginine). The large cytoplasmic loop located between the M4 and M5 transmembrane domains of the ATP13A2 protein (Fig. [1d](#Fig1){ref-type="fig"}) contains the catalytic autophosphorylation domain (P domain, including an N-terminal and C-terminal part) and the nucleotide binding domain (N domain, necessary for ATP binding) \[[@CR9], [@CR14]\]. The presence of an arginine in position 877 places a net positive charge next to the highly conserved negatively charged aspartic acid in position 878, in a very important motif within the C-terminal part of the P domain (Fig. [1d](#Fig1){ref-type="fig"}).

Structural studies of a similar P-type cationic pump, the calcium ATPase of skeletal muscle sarcoplasmic reticulum (SERCA1), revealed that the conserved aspartic acid corresponding to Asp-878 in ATP13A2 is one of the most critical residues for the ATP hydrolysis and is spatially very close to the aspartic acid residue (Asp351, corresponding to Asp513 in ATP13A2) which provides the autophosphorylation site \[[@CR14]\]. Thus, the G877R mutation is very likely to interfere with the ATPase and autophosphorylation activity of ATP13A2, necessary for the function as cationic pump. Taken together, these considerations argue strongly that the G877R mutation is deleterious for the ATP13A2 function and disease-causing when present in homozygous state.

The R481C mutation replaces a highly conserved arginine residue in the FBXO7 protein, within the so called R(Ar)DP motif (where Ar indicates any aromatic amino acid) in the C-terminal proline-rich region of the protein (Fig. [1e, h](#Fig1){ref-type="fig"}) \[[@CR15]\]. The function of the R(Ar)DP motif remains undetermined, but the proline-rich region is important for binding of the known FBXO7 substrates \[[@CR15]--[@CR17]\]. The mutation might therefore also be deleterious for the FBXO7 function. However, being found as a single heterozygous mutation in the two affected brothers and their unaffected mother, its significance for the disease causation remains unclear. This could be a coincidental finding, or the mutation could act as a disease modifier, or play some pathogenic role, together with still unknown mutations in other genes.

Different research lines point to an important role for the lysosomes in the pathogenesis of common, late-onset PD. Lysosomes are important for the degradation of the alpha-synuclein protein \[[@CR18]\], and heterozygous mutations in the *GBA* gene, encoding the lysosomal enzyme glucocerebrosidase, are an important risk factor for PD \[[@CR19]\]. Intriguingly, the ATP13A2 mRNA is highly expressed in the brain, particularly in substantia nigra, and it might be up-regulated in the brain of patients with the common late-onset idiopathic PD \[[@CR3]\]. Moreover, the ATP13A2 protein has been recently identified as a potent modifier of the toxicity induced by alpha-synuclein in animal models of PD \[[@CR10]\]. On the other hand, manganese, one possible substrate of ATP13A2, is a well-known cause of toxic parkinsonism in humans \[[@CR20]\]. Despite the rarity of PARK9 mutations, the ATP13A2 protein might therefore offer clues for understanding the pathogenesis of the common, late-onset forms of PD, linking genetic (alpha-synuclein), and environmental (manganese) factors in the disease etiology.

The clinical phenotype associated with *PARK9* mutations remains poorly defined, as only few patients with clear disease-causing genotypes have been reported. Some phenotypic variability has been described (i.e., variable presence and degrees of dementia, behavior disorders, visual hallucinations, [l]{.smallcaps}-dopa responsiveness, and disease progression). Our proband resembles indeed the previously reported PARK9 cases, and his phenotype is compatible with the clinical diagnosis of KRS. The sub-continuous mini-myoclonus present in the lower facial muscles is reminiscent of the facial--faucial--finger mini-myoclonus described in the original KRS patients \[[@CR2]\] and other PARK9 cases \[[@CR3], [@CR5]\]. Remarkably, the younger brother, apart from a moderate cognitive deficit, remains otherwise asymptomatic at the age of 31 years, and only the neurological examination revealed a mild pyramidal--extra-pyramidal involvement. This marked phenotypic variability has not been previously described in patients with identical PARK9 mutations. It could be the result of the action of genetic or environmental modifiers, or both. An aggravating effect for the perinatal brain sufferance in the proband could not be excluded; however, the severity of his phenotype is similar to that in the other PARK9 patients, and therefore, a protective effect in the proband's brother appears more likely. Mutations in the other known genes for early-onset PD (apart from the *FBXO7* heterozygous mutation) were excluded in the proband, and therefore they cannot play a role as aggravating factors. Environmental factors could include the role of some cations, according to the evidence that the ATP13A2 protein is involved in their transport from the cytosol to the lysosomal lumen \[[@CR10], [@CR11]\]. However, the blood levels of manganese, cadmium, nickel, and selenium were normal in both sibs. Furthermore, the siblings have been living with their parents in the same place, being likely exposed to the same environment.

In both sibs, the brain MRI showed diffuse brain atrophy, more marked in the proband, and the DaTSCAN SPECT showed marked nigrostriatal dopaminergic defects, again more marked in the proband, and similar to those reported in advanced idiopathic PD. The neurophysiologic investigation confirmed the involvement of the pyramidal tract and showed the normality of the large myelinated peripheral fibers and of the somatosensory system.

Recently, hypointense signals in the basal ganglia in MRI T2\*-weighted scans, suggesting iron accumulation, have been reported in a patient with homozygous PARK9 mutation \[[@CR6]\]. Based on this finding, it has been suggested to classify PARK9 within the neurodegenerations with brain iron accumulation \[[@CR6]\]. The MRI studies in other previously reported PARK9 cases did not include T2\*-weighted scans \[[@CR2], [@CR5]\] and were therefore inconclusive concerning the iron accumulation. Using a comprehensive MRI protocol that includes T2\*-weighted scans, we did not find evidence of metal accumulation in the basal ganglia of both sibs reported here. Brain metal accumulation seems therefore not a constant feature in PARK9, even after three decades of disease course. Perhaps brain metal accumulation occurs in the cases with *ATP13A2* mutations leading to the most severe loss of protein function, such as that present in the patient reported elsewhere \[[@CR6]\] (p.Thr367ArgfsX29, causing frameshift and protein truncation), while in some patients with missense mutations a residual protein function is retained and brain metal accumulation does not occur.

In conclusion, this family, the third reported with homozygous PARK9 mutations and the first with mutations in two genes for atypical juvenile parkinsonism, illustrates that PARK9-linked disease might display wide intra-familial clinical variability and present with milder phenotypes, suggesting the existence of strong, still unknown, modifiers.
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